Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer
David Avigan(Beth Israel Deaconess Medical Center), Donald Küfe(Dana-Farber Cancer Institute), L. Kennedy, Paul G. Richardson(Harvard University), Daire J. Hurley(Mater Misericordiae University Hospital), Jianlin Gong(Harvard University), Nancy Giallombardo(Beth Israel Deaconess Medical Center), Zhiyou Wu(Dana-Farber Cancer Institute), J Levine, David F. McDermott(Beth Israel Deaconess Medical Center), AD Elias(Harvard University), Robin Joyce(Beth Israel Deaconess Medical Center)
Cited by 32
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k